Abstract
TUMOUR suppressor genes, whose usual function seems to be controlling normal cell proliferation1,2, have been implicated in many inherited and sporadic forms of malignancies (for reviews, see refs 3 and 4). Much evidence supports the concept of tumour formation by loss-of-function mutations in suppressor genes, as predicted by the two-hit model of Knudson5 and DeMars6. The suppressor gene, p53, is affected in such a manner by numerous mutations, which occur in a variety of human tumours7-10. These mutations usually represent the loss of one allele and the substitution of a single base in the other. We have now analysed the p53 gene in a family affected by Li–Fraumeni syndrome11, a rare autosomal dominant syndrome characterized by the occurrence of diverse mesenchymal and epithelial neoplasms at multiple sites. In some instances the neoplasms seem to be related to exposure to carcinogens, including ionizing radiation. The Li–Fraumeni family that we studied had noncancerous skin fibroblasts (NSF) with an unusual radiation-resistant phenotype12–15. DNA derived from the NSF cells of four family members, spanning two generations, had the same point mutation in codon 245 (GGC→GAC) of the p53 gene. This mutation leads to substitution of aspartic acid for glycine in one of the regions identified9 as a frequent target of point mutations in p53. The NSF cell lines with the mutation also retained the normal p53 allele. This inherited p53 mutation may predispose the members of this family to increased susceptibility to cancer.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 51 print issues and online access
$199.00 per year
only $3.90 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Cooper, J. A. & Whyte, P. Cell 58, 1009–1011 (1989).
Levine, A. J. Virology 177, 419–426 (1990).
Seemayer, T. A. & Cavenee, W. K. Lab. Invest. 60, 585 (1989).
Stanbridge, E. J. Cancer Cells 1, 31–33 (1989).
Knudson, A. G. Proc. natn. Acad. Sci. U.S.A. 68, 820–823 (1971).
DeMars, R. In 23rd A. Symp. Fund. Cancer Res. 1969, 105–106 (William and Wiklings, Baltimore, 1970).
Baker, S. J. et al. Science 244, 217–220 (1989).
Takahashi, R. et al. Science 246, 491–494 (1989).
Nigro, J. M. et al. Nature 342, 705–708 (1989).
Mulligan, L. M., Matlashewski, G. J., Scrable, H. J. & Cavenee, W. K. Proc. natn. Acad. Sci. U.S.A. 87, 5863–5867 (1990).
Li, F. P. & Fraumeni, J. F. Jr Ann. intern. Med. 71, 747–751 (1969).
Blattner, W. A. et al. J. Am. med. Ass. 241, 259–261 (1979).
Bech-Hansen, N. T. et al. Lancet i, 1335–1337 (1981).
Chang, E. H. et al. Science 237, 1036–1039 (1987).
Pirollo, K. F. et al. Int. J. Radiat. Biol. 55, 783–796 (1989).
Gannon, J. V., Greaves, R., Iggo, R. & Lane, D. P. EMBO J. 9, 1595–1602 (1990).
Eliyahu, D. et al. Oncogene 3, 313–321 (1988).
Herskowitz, I. Nature 329, 219–222 (1987).
Finlay, C. A., Hinds, P. W. & Levine, A. J. Cell 57, 1083–1093 (1989).
Mercer, W. E. et al. Proc. natn. Acad. Sci. U.S.A. 87, 6166–6170 (1990).
Baker, S. J., Markowitz, S., Fearon, E. R., Willson, J. K. V. & Vogelstein, B. Science 249, 912–915 (1990).
Lane, D. P. & Crawford, L. V. Nature 278, 261–263 (1979).
Linzer, D. I. H. & Levine, A. J. Cell 17, 43–52 (1979).
Sarnow, P., Ho,, Y. S., Williams, J. & Levine, A. J. Cell 28, 387–394 (1982).
Werness, B. A., Levine, A. J. & Howley, P. M. Science 248, 76–79 (1990).
Mercer, W. E., Nelson, D., Deleo, A. B., Old, L. J. & Baserga, R. Proc. natn. Acad. Sci. U.S.A. 79, 6309–6312 (1982).
Malkin, D. et al. Science 250, 1233–1238 (1990).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Srivastava, S., Zou, Z., Pirollo, K. et al. Germ-line transmission of a mutated p53 gene in a cancer-prone family with Li–Fraumeni syndrome. Nature 348, 747–749 (1990). https://doi.org/10.1038/348747a0
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1038/348747a0
This article is cited by
-
Genomic and functional impact of Trp53 inactivation in JAK2V617F myeloproliferative neoplasms
Blood Cancer Journal (2024)
-
Breast cancer genomes from CHEK2 c.1100delC mutation carriers lack somatic TP53 mutations and display a unique structural variant size distribution profile
Breast Cancer Research (2023)
-
Li–Fraumeni syndrome in Tunisian carriers with different and rare tumor phenotype: genotype–phenotype correlation
BMC Medical Genomics (2022)
-
Utilizing Carbon Ions to Treat Medulloblastomas that Exhibit Chromothripsis
Current Stem Cell Reports (2022)
-
Clinical and genetic characteristics of children with acute lymphoblastic leukemia and Li–Fraumeni syndrome
Leukemia (2021)
Comments
By submitting a comment you agree to abide by our Terms and Community Guidelines. If you find something abusive or that does not comply with our terms or guidelines please flag it as inappropriate.